3D graphene bioscaffold platform for cellular therapeutics and drug delivery
General Graphene, a pure-play CVD graphene foundry with proprietary roll-to-roll production capabilities, offers large-scale, high-quality graphene for 3D bioscaffold applications in cellular therapeutics. The company seeks collaborators to validate graphene as a drug delivery platform, with an initial focus on Type 1 diabetes treatment through localized co-transplantation of islet cells and mesenchymal stem cells.
Overview
General Graphene is a pure-play chemical vapor deposition (CVD) graphene foundry with proprietary roll-to-roll manufacturing capabilities that enable production volumes and costs far exceeding industry norms. The company is positioned to supply consistent, high-quality graphene for 3D bioscaffold applications in cellular therapeutics, addressing a critical bottleneck identified in published research: reliable access to sufficient quantities of uniform graphene material. The initial target application is localized drug delivery for Type 1 diabetes, where 3D graphene bioscaffolds could enable co-transplantation of insulin-producing islet cells and mesenchymal stem cells.
Technical specifications
- Roll-to-roll CVD graphene production enabling scalable, cost-effective manufacturing
- Consistent, high-quality graphene output that resolves the material supply challenges cited in prior bioscaffold research
- 3D graphene bioscaffold format suitable for localized cell delivery and therapeutic applications
- Application-ready graphene platform adaptable to multiple cellular therapeutic use cases beyond diabetes treatment
- Collaborative development model pairing graphene manufacturing expertise with cell therapy and biomedical research partners
Technology readiness level
The graphene production technology is commercially validated through General Graphene's foundry operations. The bioscaffold application is at an early research stage, with no in-house biological validation completed to date. The company has initiated a collaboration with Dr. Avnesh Thakor at Stanford, whose published work demonstrated proof-of-concept for graphene bioscaffolds in islet and stem cell co-transplantation. Future validation efforts will focus on partnering with researchers and companies capable of conducting biological testing, leveraging General Graphene's ability to supply the consistent graphene material that prior researchers identified as the primary obstacle to advancement.
About Graphene Integrations
Graphene Integrations is a technology firm focusing on practical applications of graphene. Likely founded by material scientists, it aims to commercialize graphene beyond electronics. The choice of Manchester hints at links to the University of Manchester (a graphene research hub). They provide solutions in various sectors and have recently spotlighted food packaging as a promising field.
delivered to your inbox.